{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:08:32Z","timestamp":1790770112392,"version":"4.1.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2019,4,18]]},"DOI":"10.3233\/cbm-182193","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T16:37:46Z","timestamp":1553618266000},"page":"439-447","source":"Crossref","is-referenced-by-count":7,"title":["Low absolute NK cell counts in peripheral blood are associated with inferior survival in patients with mantle cell lymphoma"],"prefix":"10.1177","volume":"24","author":[{"given":"Xiao-Hui","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"},{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"},{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hua","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Yuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"},{"name":"Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China"},{"name":"Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/CBM-182193_ref1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","article-title":"Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"key":"10.3233\/CBM-182193_ref2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.3233\/CBM-182193_ref3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","article-title":"Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network","volume":"2","author":"Klapper","year":"2009","journal-title":"J Hematop"},{"key":"10.3233\/CBM-182193_ref4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"key":"10.3233\/CBM-182193_ref5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hon.2188","article-title":"Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma","volume":"34","author":"Yoo","year":"2016","journal-title":"Hematol Oncol"},{"key":"10.3233\/CBM-182193_ref6","doi-asserted-by":"crossref","first-page":"513702","DOI":"10.1155\/2012\/513702","article-title":"Molecular action of lenalidomide in lymphocytes and hematologic malignancies","volume":"2012","author":"McDaniel","year":"2012","journal-title":"Adv Hematol"},{"key":"10.3233\/CBM-182193_ref7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.5045\/br.2014.49.3.162","article-title":"Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"49","author":"Kim","year":"2014","journal-title":"Blood Res"},{"key":"10.3233\/CBM-182193_ref8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.leukres.2013.07.038","article-title":"Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma","volume":"37","author":"Shafer","year":"2013","journal-title":"Leuk Res"},{"key":"10.3233\/CBM-182193_ref10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjh.12409","article-title":"Prognostic impact of monocyte count at presentation in mantle cell lymphoma","volume":"162","author":"von Hohenstaufen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.3233\/CBM-182193_ref11","first-page":"342","article-title":"The extravascular development of the monocyte observed in vivo","volume":"20","author":"Ebert","year":"1939","journal-title":"Brit J Exp Pathol"},{"key":"10.3233\/CBM-182193_ref12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1615\/JEnvironPatholToxicolOncol.2013007930","article-title":"The prognostic role of tumor-associated macrophages and dendritic cells in classic Hodgkin\u2019s lymphoma","volume":"32","author":"Abdou","year":"2013","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"10.3233\/CBM-182193_ref13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/10428194.2010.529204","article-title":"Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified","volume":"52","author":"Zhang","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.3233\/CBM-182193_ref14","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"10.3233\/CBM-182193_ref15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1084\/jem.20150295","article-title":"The interaction of anticancer therapies with tumor-associated macrophages","volume":"212","author":"Mantovani","journal-title":"J Exp Med"},{"key":"10.3233\/CBM-182193_ref16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/pin.12259","article-title":"Role of tumor-associated macrophages in hematological malignancies","volume":"65","author":"Komohara","journal-title":"Pathol Int"},{"key":"10.3233\/CBM-182193_ref17","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/ni1138","article-title":"Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming","volume":"5","author":"Martin-Fontecha","year":"2004","journal-title":"Nat Immunol"},{"key":"10.3233\/CBM-182193_ref18","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.4049\/jimmunol.136.12.4480","article-title":"The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes","volume":"136","author":"Lanier","year":"1986","journal-title":"J Immunol"},{"key":"10.3233\/CBM-182193_ref19","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1084\/jem.171.5.1509","article-title":"Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors","volume":"171","author":"Caligiuri","year":"1990","journal-title":"J Exp Med"},{"key":"10.3233\/CBM-182193_ref20","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1002\/1521-4141(2001010)31:10<3121::AID-IMMU3121>3.0.CO;2-4","article-title":"CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells","volume":"31","author":"Jacobs","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.3233\/CBM-182193_ref21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/14653249.2010.515582","article-title":"A phase II et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer","volume":"13","author":"Geller","year":"2011","journal-title":"Cytotherapy"},{"key":"10.3233\/CBM-182193_ref22","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s00262-010-0904-3","article-title":"A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer","volume":"59","author":"Iliopoulou","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.3233\/CBM-182193_ref23","first-page":"1861","article-title":"Autologous natural killer cell therapy for human recurrent malignant glioma","volume":"24","author":"Ishikawa","year":"2004","journal-title":"Anticancer Res"},{"key":"10.3233\/CBM-182193_ref24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"10.3233\/CBM-182193_ref25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"10.3233\/CBM-182193_ref26","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2011-05-351411","article-title":"Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism","volume":"118","author":"Veeramani","year":"2011","journal-title":"Blood"},{"key":"10.3233\/CBM-182193_ref27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.14866","article-title":"Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity","volume":"179","author":"Hagner","year":"2017","journal-title":"Br J Haematol"},{"key":"10.3233\/CBM-182193_ref28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"10.3233\/CBM-182193_ref29","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-182193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:06:56Z","timestamp":1777385216000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/CBM-182193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,18]]},"references-count":28,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/cbm-182193","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,18]]}}}